



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 20<sup>TH</sup> JANUARY 2021

#### PRESENT:

Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr T McKenzie (TM)	GP East Lancs
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mr U Akram (UK)	Pharmacist, Lancashire Care Foundation Trust

#### IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

#### 2021/001: APOLOGIES:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG

ELMMB would like to acknowledge and thank Catherine Dugdale for her contributions to the Medicine Management Board over many years and wish her well in her new post.

#### 2021/002: DECLARATION OF INTEREST

None declared – relevant to agenda items.

#### 2021/003: MINUTES OF OCTOBER Teams MEETING:

Accepted as a correct record.

#### 2021/004: MATTERS ARISING:

**2019/131: Treatment of Vitamin B12 Deficiency Draft** – pathway to be brought to ELMMB in early 2021.

**2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta®** - JV arranging meeting in early 2021.

**2020/092: Drug Safety Update – Denosumab** – To be brought to ELMMB in early 2021 and include endocrinologists.

**2020/107: Adrenaline Auto Injector Position Statement & Patient Information Leaflet** – To be brought to ELMMB in early 2021.

**2020/129: Remdesivir Commissioning Update** – prescribing information for Remdesivir in the trust acknowledged.

**2020/Additional item: Goserelin for prostate cancer shared care** – on main agenda

### **2021/005: COVID-19 VACCINE POLICY, PGD's, NATIONAL PROTOCOLS AND ASSOCIATED DOCUMENTS**

The COVID-19 trust vaccine policy, national PGD's, national protocols and their associated documents are for information. They have all been approved for use via Chair's action.

**Resolved: COVID-19 related documents approved for use.**

### **2021/006: NEW PRODUCT REQUEST – DIAZOXIDE TABLETS**

Requested by endocrinologists for the treatment of chronic intractable hypoglycaemia when standard therapy has failed to maintain blood glucose levels. This is anticipated to be for a small number of patients.

It was agreed to add to formulary with red traffic light.

**Resolved: Diazoxide tablets added to formulary.**

**Traffic Light: RED**

### **2021/007: NEW PRODUCT REQUEST – COVID-19 mRNA Vaccine BNT162b2**

The PfizerBioNTech vaccine is approved for use for the COVID-19 vaccination programme.

**Resolved: COVID-19 mRNA Vaccine BNT162b2 added to formulary.**

**Traffic Light: GREEN**

### **2021/008: NEW PRODUCT REQUEST – COVID-19 vaccine (ChAdOx1-S [recombinant])**

The AstraZenica vaccine is approved for use for the COVID-19 vaccination programme.

**Resolved: COVID-19 vaccine (ChAdOx1-S [recombinant]) added to formulary.**

**Traffic Light: GREEN**

### **2021/009: RITUXIMAB-LENOLIDAMIDE COMPASSIONATE USE**

The compassionate use of rituximab-lenolidamide has been approved by Chair's action for a single patient. Acknowledged by ELMMB.

**Resolved: ELMMB acknowledge compassionate use of Rituximab-Lenolidamide**

## **2021/010: TOCILUZUMAB USE FOR COVID-19 ON CRITICAL CARE**

Guidance for use of tocilizumab for COVID-19 on critical care for information.

**Resolved: ELMMB acknowledge guidance for use of Tocilizumab for COVID-19**

## **2021/011: LSCMMG CONSULTATIONS (FOR FEBRUARY LSCMMG)**

None received.

## **2021/012: LSCMMG Recommendations**

**Psoriasis in Primary Care Guideline – updated** – accepted as written for use in ELHE.

**LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway** – concerns were raised that this pathway does not include upper UTI prophylaxis, it only has referral for patients with red flag symptoms and does not follow NICE guidance. Feedback to be provided to LSCMMG that this pathway appears to conflict with NICE.

Not accepted for use in ELHE – the NICE pathway will be used in ELHE.

**Apomorphine Shared Care Guidelines** – Accepted for use in ELHE.

**Dapagliflozin Shared Care Guidelines** – Accepted for use in ELHE.

## **2021/013: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS**

The approvals by the JCCCG's were on the agenda for information. It is unclear which recommendations from LSCMMG are going to JCCCGs (managers) for approval and which go to local groups (ELMMB).

LR to clarify which items are to go to Joint Committee of CCGs with the need to take into account local commissioning arrangements and local nuances.

Approval / acknowledgement of current JCCCG new products & pathways deferred to a future ELMMB meeting.

**Action: LR to clarify with LSCMMG which items need approval at Lancs & South Cumbria level (JCCCGs) and which require local nuances to account for local commissioning pathways.**

## **2021/014: FORMULARY UPDATES**

**Dupilumab (Dupixant®)** – change from pre-filled syringes to pre-filled pens.

**Hydrocortisone rectal foam (Colifoam®)** – discontinued. Remove from formulary.

**Resolved: Formulary to be updated as above.**

### **2021/015: ELHT: GUIDELINE FOR THE USE OF NATPAR® (PARATHYROID HORMONE) FOR CHRONIC HYPOPARATHYROIDISM**

Guideline produced to support the use of Natpar® which was added to the formulary last year (red traffic light.)

Approved by ELMMB. Also to be approved by directorate.

**Resolved: Natpar® (parathyroid hormone) guideline approved.**

### **2021/016: ELHE: GOSERELIN SHARED CARE GUIDELINE**

The goserelin 3.6mg shared care guideline has been updated as previously agreed with the first dose for prostate cancer now to be administered in primary care. Secondary care will now take responsibility for the first month only of treatment for breast cancer and gynaecological conditions rather than three months. The GPs stated that the 10.8mg (3 monthly injection) goserelin implant is mainly used for prostate cancer so it would make sense for this to be included in the 10.8mg shared care guideline.

To feed back comments to VG for updating and to bring both documents back to next meeting.

**Action: VG to update the goserelin 10.8mg shared care guideline.**

### **2021/017: NICE RECOMMENDATIONS (from November)**

Drug-eluting stents for the treatment of coronary artery disease (TA152 updated)

Guidance on the use of coronary artery stents (TA71 updated)

Siponimod for treating secondary progressive multiple sclerosis [TA656] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Carfilzomib for previously treated multiple myeloma (TA657) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Galcanezumab for preventing migraine (TA659) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned - Blueteq form required

**Traffic Light: RED**

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) [TA662]

**Traffic light: BLACK**

## **2021/018: NICE RECOMMENDATIONS (from December)**

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia [TA663] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Liraglutide for managing overweight and obesity (TA664) is recommended as an option by NICE. To be managed by tier 3 weight management services.

CCG Commissioned - the local tier 3 service does not have prescribers.

**Action: LR to discuss with LSCMMG commissioning and pathway for tier 3 weight management services.**

Upadacitinib for treating severe rheumatoid arthritis (TA665) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned - Blueteq form required

**Traffic Light: RED**

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

## **STANDING ITEMS**

### **2021/019: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – November 2020**

Minutes acknowledged

### **2021/020: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA FT D&T MINUTES – November 2020**

**DATE OF NEXT MEETING – Wednesday 17<sup>th</sup> February 2021 12.30pm via ‘Microsoft Teams’**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 20<sup>TH</sup> JANUARY 2021**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
2019/131	<b>Treatment Of Vitamin B12 Deficiency Draft</b> – pathway to be developed.	LR/JV	Mar 21
2020/015	<b>New Product request – Relvar Ellipta® &amp; Anoro Ellipta®</b> - meeting to be arranged to consider place on primary care guidelines	JV	Mar 21
2020/092	<b>Drug Safety Update – Denosumab</b> Invite representatives from rheumatology, MSK & medicine for older people to next meeting	CW/AG/LR	Mar 21
2020/107	<b>Adrenaline Auto Injector Position Statement &amp; Patient Information Leaflet</b> – discuss policies & procedures in schools with LCC	JV	Mar 21
2021/012	<b>LSCMMG Recommendations - LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway</b> – send comments to LSCMMG	CW	Feb 21
2021/013	<b>Joint Committee Of CCGs Commissioning Decisions</b> – discuss processes for approval of new products/ guidelines/pathways once approved by LSCMMG.	LR	Feb 21
2021/016	<b>ELHE: GOSERELIN SHARED CARE GUIDELINE</b> – also amend shared care for 10.8mg implant	VG	Feb 21
2021/018	<b>NICE Recommendations (from December)</b> - Liraglutide for managing overweight and obesity (TA664) – discuss with LSCMMG commissioning pathway for tier 3 weight management	LR	Feb 21